Elevar Therapeutics Reports P-III Study (CARES 310) Results of Rivoceranib + Camrelizumab as a 1L Therapy for Unresectable Hepatocellular Carcinoma
Shots:
- The P-III study results published in The Lancet evaluating Elevar’s rivoceranib (250mg, qd) + camrelizumab (200mg, IV, q2w) vs sorafenib (400mg, BID) in 543 patients at 95 study sites across 13 countries/regions showed a significant & clinically meaningful prolonged OS and PFS
- Improved ORR over sorafenib & efficacy results were generally consistent across all subgroups. The company continues to advance rivoceranib as monotx. for adenoid cystic carcinoma (ACC), and as monotx. and combination therapies for other tumor cell types
- Rivoceranib, under the name apatinib is approved in China for advanced gastric cancer & in 2L advanced HCC. Camrelizumab, under the brand name AiRuiKa, is currently approved for 8 indications in China
Ref: Globenewswire | Image: Elevar Therapeutics
Related News:- Elevar Therapeutics Reports the US FDA Acceptance of NDA for Rivoceranib + Camrelizumab as 1L Treatment for Unresectable Hepatocellular Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
